ONCOPRO COMPREHENSIVE CANCER PANEL 161 GENES Test
Test Name: ONCOPRO COMPREHENSIVE CANCER PANEL 161 GENES Test
Components:
- 86 Hotspot genes
- 47 full length genes
- Copy number variations in 43 genes
- Fusions in 48 genes
Price: 8400.0 AED
Sample Condition: Submit formalin fixed paraffin embedded (FFPE) tissue block. Ship at room temperature. Block should have at least 10% tumor tissue.
Report Delivery: Sample Daily by 11 am; Report 35 Working days
Method: Next Generation Sequencing
Test Type: Cancer
Doctor: Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information: Block should have at least 10% tumor tissue.
Test Details:
The ONCOPRO Comprehensive Cancer Panel is a genetic test that analyzes 161 genes associated with various types of cancer. The test uses next-generation sequencing technology to identify mutations and other genetic alterations that may contribute to the development and progression of cancer. The genes included in the panel are selected based on their known association with cancer, including genes involved in cell growth and division, DNA repair, and tumor suppression.
The test can detect a range of genetic alterations, including single nucleotide variants, small insertions and deletions, copy number changes, and gene fusions. The ONCOPRO Comprehensive Cancer Panel is used to help diagnose cancer, determine prognosis, and guide treatment decisions. The test can identify specific mutations that may be targeted by certain cancer therapies, and can also help identify patients who may be at increased risk for certain types of cancer based on their genetic profile.
The test is typically performed on a tumor sample, but can also be performed on blood or other tissue samples. Results are typically available within a few weeks and are reported in a detailed clinical report that includes information on any identified mutations, their clinical significance, and potential treatment options.
| Test Name | ONCOPRO COMPREHENSIVE CANCER PANEL 161 GENES Test |
|---|---|
| Components | *86 Hotspot genes*47 full length genes*Copy number variations in 43 genes*Fusions in 48 genes |
| Price | 8400.0 AED |
| Sample Condition | Submit formalin fixed paraffin embedded (FFPE) tissue block.Ship at room temperature. Block should have atleast 10% tumor tissue. |
| Report Delivery | Sample Daily by 11 am; Report 35 Working days |
| Method | Next Generation Sequencing |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | MOLECULAR DIAGNOSTICS |
| Pre Test Information | Block should have atleast 10% tumor tissue. |
| Test Details | The ONCOPRO Comprehensive Cancer Panel is a genetic test that analyzes 161 genes associated with various types of cancer. The test uses next-generation sequencing technology to identify mutations and other genetic alterations that may contribute to the development and progression of cancer. The genes included in the panel are selected based on their known association with cancer, including genes involved in cell growth and division, DNA repair, and tumor suppression. The test can detect a range of genetic alterations, including single nucleotide variants, small insertions and deletions, copy number changes, and gene fusions. The ONCOPRO Comprehensive Cancer Panel is used to help diagnose cancer, determine prognosis, and guide treatment decisions. The test can identify specific mutations that may be targeted by certain cancer therapies, and can also help identify patients who may be at increased risk for certain types of cancer based on their genetic profile. The test is typically performed on a tumor sample, but can also be performed on blood or other tissue samples. Results are typically available within a few weeks and are reported in a detailed clinical report that includes information on any identified mutations, their clinical significance, and potential treatment options. |
